A double-blind, placebo-controlled study of rabeprazole 20 mg maintenance intermittent therapy following acute treatment in patients with symptomatic gastroesophageal reflux disease.

Trial Profile

A double-blind, placebo-controlled study of rabeprazole 20 mg maintenance intermittent therapy following acute treatment in patients with symptomatic gastroesophageal reflux disease.

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jun 2013

At a glance

  • Drugs Rabeprazole (Primary)
  • Indications Gastro-oesophageal reflux; Heartburn
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Feb 2010 Results have been published in Alimentary Pharmacology and Therapeutics.
    • 17 Dec 2009 Actual patient number (200) added as reported by ClinicalTrials.gov.
    • 17 Jul 2008 The actual completion date for this trial has been identified as June 2008, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top